Preclinical studies have demonstrated that TD139 is effective on all of the major IPF cell types, including fibroblast activation, Gal‐3/macrophage phenotype expression, a reduction in the activity of important profibrotic growth factors on myofibroblasts, and epithelial‐mesenchymal transition inhibition.90, 91, 93. The gene discussed is LGALS3; the disease is idiopathic pulmonary fibrosis.